Similar articles

• [The effects of non-pharmacotherapy in decreasing the levels of serum lipid in patients with hyperlipidemia].

  Chen J, Wang J, Li N, Zhang M, Fu Z, Zhang L, Yin G, Wu T. Chen J, et al. Zhonghua Liu Xing Bing Xue Za Zhi. 2002 Apr;23(2):138-41. Zhonghua Liu Xing Bing Xue Za Zhi. 2002. PMID: 12015099 Chinese.
• [Cost-benefit analysis of the therapy of lipid metabolism disorders].

  Karádi I. Karádi I. Orv Hetil. 1996 May 26;137(21):1164. Orv Hetil. 1996. PMID: 8757110 Hungarian. No abstract available.
• Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.

  Kang HY, Ko SK, Liew D. Kang HY, et al. Clin Ther. 2009 Dec;31(12):2919-30; discussion 2916-8. doi: 10.1016/j.clinthera.2009.12.013. Clin Ther. 2009. PMID: 20110032
• [Hyperlipidemia and cerebrovascular disease].

  Kimura Y, Uchiyama S. Kimura Y, et al. Nihon Rinsho. 2001 Feb;59 Suppl 2:685-9. Nihon Rinsho. 2001. PMID: 11351670 Review. Japanese. No abstract available.
• [Significance of setting standards and guidelines for management of patients with hyperlipidemia].

  Kotake H, Oikawa S. Kotake H, et al. Nihon Rinsho. 2001 Mar;59 Suppl 3:492-9. Nihon Rinsho. 2001. PMID: 11347119 Review. Japanese. No abstract available.